Retatrutide: 28% Weight Loss! But There's a Catch. EASD 2026
The Downsized — Retatrutide: 28% Weight Loss! But There's a Catch. EASD 2026
Channel: DOWNSIZED · Our label: Patient-experience channel — GLP-1 journey, daily · Source: youtube.com/watch?v=cQKcKcH7VMk
What this video covers
Retat true is the most anticipated obesity drug in the world and the full results are finally out. But it’s not the whole story and it’s not for everybody. My name is Christopher Durham and welcome to the downsized. If you’re new here, my wife Lorraine and I are a regular suburban couple who started treating our obesity with Tzeptide in September 2023.
Summary drawn from this video’s own transcript (banked in our research library, pulled 2026-11-07). Claims below are the speaker’s — attributed, not endorsed. This site publishes no dosing, protocol, or sourcing information.
Key points, in the speaker’s own framing
- Most were rated mild or moderate, but moderate in a clinical trial can still ruin your week.
- If that’s you and Retatride gets approved, bring it up with your doctor.
- Clinical trials should help us understand those differences, not hand us another way to feel like we came up short.
- And if reatrite is approved, doctors and patients are going to be having that conversation a lot.
- Now, as of October 2026, Retatrutide is not FDA approved.
- If you’re seeing redotride sold online as a research peptide as a not for human use medication drug, Lily says the drug is legally available only to people in its clinical trials.
Read next
Educational information only — not medical advice. Peptides discussed on this page include substances that are not FDA-approved.